On the evening of September 12, 2007, the National Development Fund announced that it was taking a 40 % stake in TaiMed Biologics, a company that would be formed the following day. TaiMed named former vice premier Tsai Ing-wen its first chair and TNX-355, acquired from Genentech for US $ 100 million, its first product.
2007 年 9 月 12 日晚上，各大媒體接到緊急通知，國發基金入股 40％的「宇昌生技」隔天就要正式成立，由當時已卸任行政院副院長的民進黨現任黨主席蔡英文出任董事長，推出的第一件生技新藥，就是以總價 1 億美元購自 Genentech 的 TNX-355。